Patients highlight commonalities in rare diseases that could streamline drug development

Rare disease patients, advocates and caregivers who spoke at an FDA workshop on Monday highlighted multiple common symptoms across various diseases that could be used to streamline drug development. Attendees also cited the need for patients

Read the full 360 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE